Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
企業コードCSTL
会社名Castle Biosciences Inc
上場日Jul 25, 2019
最高経営責任者「CEO」Maetzold (Derek J)
従業員数761
証券種類Ordinary Share
決算期末Jul 25
本社所在地505 S Friendswood Drive
都市FRIENDSWOOD
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号77546
電話番号18667889007
ウェブサイトhttps://castlebiosciences.com/
企業コードCSTL
上場日Jul 25, 2019
最高経営責任者「CEO」Maetzold (Derek J)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし